© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer
COVID-19 Death Toll in NYC Calls Attention to Racial Disparities
July 02, 2020
In New York City, high cases of COVID-19 continue to be reported with a high prevalence among racial and ethnic minorities.
Combination Immunotherapy Appears Promising in Breast Cancer Subtypes
June 25, 2020
Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Investigating How to Help Patients With Breast Cancer Stay on Therapy
June 25, 2020
Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.
Atezolizumab Plus Chemotherapy Improves Responses in Triple-Negative Breast Cancer
June 18, 2020
IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.
MonarchE Meets Primary End Point with Abemaciclib Combo in HR+, HER2- Breast Cancer
June 16, 2020
"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "
Veliparib Combination Induces Significant Improvement in PFS for BRCA-Like Advanced TNBC
June 03, 2020
“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."
Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355
June 03, 2020
Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Palbociclib Expected to Miss Its Mark in HR+, HER2– Breast Cancer
June 01, 2020
"We are disappointed [with] this outcome. Breast cancer is a leading cause of death around the world and delaying or preventing the development of metastatic disease is a significant unmet need. PALLAS is a large study with many subgroups and we are actively collaborating to determine if there are patients who may benefit from adjuvant treatment with the palbociclib combination."
Frontline Pembrolizumab Plus Chemo Shows Compelling PFS Improvement in PD-L1+ TNBC
May 29, 2020
"Pembrolizumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS as compared with chemotherapy alone for the first-line treatment of metastatic TNBC with a PD-L1 CPS of 10 or higher tumors."
Significant Delay in CNS Progression Achieved With Tucatinib Triplet in HER2+ Metastatic Breast Cancer
May 29, 2020
The addition of tucatinib to treatment with trastuzumab and capecitabine resulted in more than a 60% reduction in the risk of central nervous system progression or death in both patients with previously treated HER2-positive metastatic breast cancer who have active or stable brain metastases.